68 Ga-DOTATATE PET/CT Versus 18 F-FDG PET/CT in TENIS Syndrome: A Head-to-Head Comparison With Elevated and Suppressed TSH Levels in Papillary Thyroid Carcinoma-A Pilot Study.

Autor: Almeida LS; From the Division of Nuclear Medicine, Department of Radiology, Campinas State University (UNICAMP), São Paulo, Campinas, Brazil., Santos A, Assumpção L; Division of Endocrinology, Department of Internal Medicine Campinas State University (UNICAMP), São Paulo, Campinas, Brazil., Costa TO, Araujo M; From the Division of Nuclear Medicine, Department of Radiology, Campinas State University (UNICAMP), São Paulo, Campinas, Brazil., Lima M, Zantut-Wittmann DE; Division of Endocrinology, Department of Internal Medicine Campinas State University (UNICAMP), São Paulo, Campinas, Brazil., Etchebehere E
Jazyk: angličtina
Zdroj: Clinical nuclear medicine [Clin Nucl Med] 2024 Nov 01; Vol. 49 (11), pp. 1004-1013. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1097/RLU.0000000000005366
Abstrakt: Background: TENIS syndrome is characterized by reduced expression of sodium-iodine symporter, rising serum thyroglobulin (Tg) levels, and negative whole-body 131 I scans. In such patients, somatostatin receptor imaging with 68 Ga-DOTATATE PET/CT (somatostatin receptor [SSR] PET/CT) and 18 F-FDG PET/CT (FDG PET/CT) can identify metastases and were compared under 2 conditions: elevated (eTSH) and suppressed (sTSH) TSH serum levels. Potential candidates for peptide receptor radionuclide therapy (PRRNT) were identified in 15 patients prospectively enrolled. All patients underwent 4 examinations. Images were blindly evaluated for differences in SUV max values and lesion detectability. Reference standard consisted of neck ultrasound, CT, MRI, PET/CT, biopsy, and follow-up. Three patients were received PRRNT.
Results: sTSH SSR PET/CT detected a greater number of cervical ( P = 0.0253 and P = 0.0176) and distant LNs ( P = 0.0253 and P = 0.0391) when compared with sTSH FDG PET/CT, respectively, in a per-patient and on a per-lesion based analysis. Likewise, eTSH SSR PET/CT detected a greater number of patients with local recurrences ( P = 0.0455) and distant LN metastases ( P = 0.0143). Per-lesion analysis revealed greater number of cervical and distant LNs ( P = 0.0337 and P = 0.0039, respectively) when compared with eTSH FDG PET/CT. There was no difference in detection of distant metastases by both tracers for lung and bone metastases (κ = 1). Both skeletal and pulmonary lesions were also detected by conventional CT part of FDG or DOTATATE PET/CT scans. TSH stimulation had no additional value in a per-patient analysis for both FDG and DOTATATE PET scans (κ varying from 0.6087 to 1). However, TSH stimulation led to more lesion identifications in DOTATATE PET/CT; most of those metastases were not confirmed by the reference standard leading to a decrease in specificity (84% vs 74%). One of 3 patients submitted to 3 cycles of PRRNT presented with a visual partial response, a 20% reduction in quantitative analyses, and stable disease regarding Tg and TgAb levels.
Conclusions: Patients with TENIS syndrome can be imaged with SSR PET/CT as well as FDG PET/CT with high overall accuracy regardless of TSH levels (86% to 92% and 92% to 85%, respectively, with eTSH and sTSH). SSR PET/CT detected a greater number of locoregional and distant LN metastases than FDG PET/CT with both sTSH and eTSH. One of 3 patients submitted to PRRNT presented a partial response to treatment. Our findings may impact in patient restaging, management, and theranostics strategies with radiolabeled somatostatin analogs.
Competing Interests: Conflicts of interest and sources of funding: This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector. The authors declare no financial (or other) conflict of interest relating to Employment or Leadership Position, Consultant or Advisory, Stock Ownership, Honoraria, Expert Testimony, Patents, Royalties, Licenses, or other Remuneration. D.E.Z.-W. had a National Council of Technological and Scientific Development Scholarship (CNPq) (303068/2021-3), and L.S.A. had a CAPES-Print Funding for doctorate Scholarship (CAPES) (88887.716546/2022-00).
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: